Hepatitis B and C in African Americans: Current Status and Continued Challenges

被引:34
作者
Forde, Kimberly A. [1 ,2 ]
Tanapanpanit, Orapin [1 ]
Reddy, K. Rajender [1 ]
机构
[1] Univ Penn, Perelman Sch Med, Div Gastroenterol & Hepatol, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
Hepatitis B; Hepatitis C; African American; Black; Disparities; ORTHOTOPIC LIVER-TRANSPLANTATION; TENOFOVIR DISOPROXIL FUMARATE; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; ADEFOVIR DIPIVOXIL; PEGINTERFERON ALPHA-2A; RACIAL-DIFFERENCES; INITIAL TREATMENT; NATURAL-HISTORY;
D O I
10.1016/j.cgh.2013.06.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Viral hepatitis remains a public health concern in the United States, resulting in excess morbidity and mortality for the individual and representing a burden to societies as evidenced by billions of dollars in health care expenditures. As with many chronic diseases, race and ethnicity influence various aspects of disease pathogenesis, including mechanisms of persistence, disease progression, disease sequelae, and response to therapy. For hepatitis B and C infections, African Americans disproportionately bear a large burden of disease in the United States. The role and importance of African American race, however, have been less well-characterized in the literature among the population of viral hepatitis-infected individuals. The differences in epidemiology, manifestations of liver disease, response to therapy, and differential trends in liver transplantation in African Americans compared with other racial and ethnic groups deserve special attention. This review will address the current status of hepatitis B and C infection in African Americans in the United States and identify some of the remaining challenges in diagnosis, characterization of natural history, and treatment. For the purposes of this review, the terms African American and black will be used interchangeably throughout the text.
引用
收藏
页码:738 / 748
页数:11
相关论文
共 100 条
[1]   Review article: chronic hepatitis C - natural history and cofactors [J].
Alberti, A ;
Vario, A ;
Ferrari, A ;
Pistis, R .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 :74-78
[2]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[3]  
[Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
[4]   The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].
Armstrong, Gregory L. ;
Wasley, Annemarie ;
Simard, Edgar P. ;
McQuillan, Geraldine M. ;
Kuhnert, Wendi L. ;
Alter, Miriam J. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714
[5]   Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].
Bacon, Bruce R. ;
Gordon, Stuart C. ;
Lawitz, Eric ;
Marcellin, Patrick ;
Vierling, John M. ;
Zeuzem, Stefan ;
Poordad, Fred ;
Goodman, Zachary D. ;
Sings, Heather L. ;
Poordad, Fred ;
Goodman, Zachary D. ;
Sings, Heather L. ;
Boparai, Navdeep ;
Burroughs, Margaret ;
Brass, Clifford A. ;
Albrecht, Janice K. ;
Esteban, Rafael .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217
[6]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[7]   Telaprevir and Boceprevir in African Americans with Genotype 1 Chronic Hepatitis C: Implications for Patients and Providers [J].
Burton, Mary Jane ;
Passarella, Michael J. ;
McGuire, Brendan M. .
SOUTHERN MEDICAL JOURNAL, 2012, 105 (08) :431-436
[8]   Liver Transplantation Outcomes Among Caucasians, Asian Americans, and African Americans with Hepatitis B [J].
Bzowej, Natalie ;
Han, Steven ;
Degertekin, Bulent ;
Keeffe, Emmet B. ;
Emre, Sukru ;
Brown, Robert ;
Reddy, Rajender ;
Lok, Anna S. .
LIVER TRANSPLANTATION, 2009, 15 (09) :1010-1020
[9]  
Center for Disease Control and Prevention, HEP B INF HLTH PROF
[10]   A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients [J].
Chang, TT ;
Gish, RG ;
Hadziyannis, SJ ;
Cianciara, J ;
Rizzetto, M ;
Schiff, ER ;
Pastore, G ;
Bacon, BR ;
Poynard, T ;
Joshi, S ;
Klesczewski, KS ;
Thiry, A ;
Rose, RE ;
Colonno, RJ ;
Hindes, RG .
GASTROENTEROLOGY, 2005, 129 (04) :1198-1209